Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel; Laboratory of Eye Research, Felsenstein Medical Research Center, Petah-Tikva, Israel; The Israeli National Hemophilia Center and the Amalia Biron Thrombosis Research Institute, Sheba Medical Center, Tel-Hashomer, Israel.
Ophthalmology Department, Rabin Medical Center, Petah-Tikva, Israel.
Exp Eye Res. 2019 Sep;186:107695. doi: 10.1016/j.exer.2019.107695. Epub 2019 Jun 12.
Activated protein C (APC) exerts diverse cell signaling pathways which results in multiple distinct cytoprotective actions. These include anti-apoptotic and anti-inflammatory activities and stabilization of endothelial and epithelial barriers. We studied the ability of APC to inhibit the leakage and the growth of newly formed as well as pre-existing choroidal neovascularization (CNV) and examined the ability of APC to stabilize the Retinal Pigmented Epithelium (RPE). We explored the contribution of Tie2 receptor to the protective effects of APC. CNV was induced by laser photocoagulation in C57BL/6J mice. APC was injected intravitreally immediately or 7 days after CNV induction. Neovascularization was evaluated on RPE-choroidal flatmounts using FITC-dextran perfusion and CD31 immunofluorescence. CNV leakage was measured by fluorescein angiography (FA). The ability of APC to stabilize the RPE barrier was evaluated in-vitro by dextran permeability and zonula occludens 1 (ZO1) immunostaining. Tie2 blocking was induced in-vivo by intraperitoneal injection of Tie2 kinase inhibitor and in-vitro by incubation with anti Tie2 antibodies. APC treatment dramatically inhibited the generation of newly formed CNV leakage sites and reversed leakage in 85% of the pre-existing CNV leaking sites. In RPE cell culture, APC induced translocation of ZO1 to the cell membrane, accompanied by reduction in permeability of the monolayer. Inhibition of Tie2 significantly decreased APC protective activities in both the mouse model and the RPE cell culture. Our results show that APC treatment significantly inhibits the leakage and growth of newly formed, as well as pre-existing CNV, and its protective activities are partially mediated via the Tie2 receptor. The data suggest that APC should be further investigated as a possible effective treatment for CNV.
活化蛋白 C(APC)发挥多种细胞信号通路,从而产生多种不同的细胞保护作用。这些作用包括抗凋亡和抗炎作用,以及稳定内皮细胞和上皮细胞屏障。我们研究了 APC 抑制新形成和已存在脉络膜新生血管化(CNV)渗漏和生长的能力,并检查了 APC 稳定视网膜色素上皮(RPE)的能力。我们探讨了 Tie2 受体对 APC 保护作用的贡献。CNV 通过激光光凝在 C57BL/6J 小鼠中诱导。APC 在 CNV 诱导后立即或 7 天内玻璃体腔内注射。使用 FITC-葡聚糖灌注和 CD31 免疫荧光在 RPE-脉络膜平面上评估新生血管化。通过荧光素血管造影(FA)测量 CNV 渗漏。通过葡聚糖通透性和封闭蛋白 1(ZO1)免疫染色在体外评估 APC 稳定 RPE 屏障的能力。Tie2 阻断通过腹腔内注射 Tie2 激酶抑制剂和体外与抗 Tie2 抗体孵育在体内诱导。APC 治疗显著抑制新形成的 CNV 渗漏部位的生成,并使 85%的已存在的 CNV 渗漏部位的渗漏逆转。在 RPE 细胞培养中,APC 诱导 ZO1 向细胞膜易位,同时单层通透性降低。Tie2 抑制显著降低了 APC 在小鼠模型和 RPE 细胞培养中的保护活性。我们的结果表明,APC 治疗显著抑制新形成和已存在的 CNV 的渗漏和生长,其保护活性部分通过 Tie2 受体介导。数据表明,APC 应作为 CNV 的一种潜在有效治疗方法进一步研究。